FDA grants expanded access to pancreatic cancer drug. The move allows wider patient use while the drug remains under regulatory review, citing urgent need.

The FDA granted expanded access to a pancreatic cancer drug, allowing it to be given to more patients while under regulatory review. The agency cited the dire need for such a treatment.